Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

A Hartman, R H N van Schaik, I P van der Heiden, M J C Broekhuis, M Meier, M L den Boer, R Pieters

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Abstract

INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.

METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.

RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.

CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.

Original languageEnglish
Pages (from-to)154-9
Number of pages6
JournalLeukemia research
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Keywords

  • ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
  • Child
  • Child, Preschool
  • Cytochrome P-450 CYP3A/genetics
  • Drug Resistance, Neoplasm/genetics
  • Female
  • Genotype
  • Humans
  • Male
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
  • Psychomotor Performance/drug effects
  • Vincristine/pharmacokinetics
  • tau Proteins/genetics

Fingerprint

Dive into the research topics of 'Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia'. Together they form a unique fingerprint.

Cite this